Biblio
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 373-81, 2016.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
,